KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román M (1,2), Baraibar I (1,2), López I (2), Nadal E (3), Rolfo C (4), Vicent S (2,5,6), Gil-Bazo I (7,8,9,10)
(1) Department of Oncology, Clínica Universidad de Navarra, 31008, Pamplona, Spain.
(2) Program of Solid Tumors and Biomarkers, Center for Applied Medical Research, Pamplona, Spain.
(3) Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.
(4) Phase I-Early Clinical Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Edegem, Belgium.
(5) Navarra Health Research Institute (IDISNA), Pamplona, Spain.
(6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(7) Department of Oncology, Clínica Universidad de Navarra, 31008, Pamplona, Spain.
(8) Program of Solid Tumors and Biomarkers, Center for Applied Medical Research, Pamplona, Spain.
(9) Navarra Health Research Institute (IDISNA), Pamplona, Spain.
(10) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Data: 19/Fev/2018Oncologia Médica
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of patients present advanced disease at onset.
However, in the last decade, multiple oncogenic driver alterations have been discovered and each of them represents a potential therapeutic target. Although KRAS mutations are the most frequently oncogene aberrations in lung adenocarcinoma patients, effective therapies targeting KRAS have yet to be developed.
Moreover, the role of KRAS oncogene in NSCLC remains unclear and its predictive and prognostic impact remains controversial. The study of the underlying biology of KRAS in NSCLC patients could help to determine potential candidates to evaluate novel targeted agents and combinations that may allow a tailored treatment for these patients.
The aim of this review is to update the current knowledge about KRAS-mutated lung adenocarcinoma, including a historical overview, the biology of the molecular pathways involved, the clinical relevance of KRAS mutations as a prognostic and predictive marker and the potential therapeutic approaches for a personalized treatment of KRAS-mutated NSCLC patients.
CITAÇÃO DO ARTIGO Mol Cancer. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x
A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.
Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.
Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.